HIV Treatment Information Base
News
New guide: HIV testing and sexual transmission
Easy to read summary of sexual risks and questions about testing.
News - latest 
HTB November/December now online 6.12.11
Online survey for London patients – please take part 24.11.11
HIV treatment guides
Take control of your treatment. Easy to read up-to-date guides.
HIV Treatment Bulletin
Technical review of the latest HIV research.
Questions and answers
Treatment questions answered by phone, email or online.
ARV4IDUs
Review of HIV drugs for injecting drug users (English & Russian).
Publications and translations
A-Z list of all our publications.
HTB South
HIV research and news for southern Africa,
Glossary
Medical words and phrases explained
Treatment manual
From CD4 and viral load to understanding clinical trials.
Workshops and training
We run workshops on any aspect of treatment.
About us
We are an HIV-positive led treatment advocacy group.
UK-CAB
Network of over 460 people in the UK involved in advocacy. Free to join.
Русский
Наш сайт уже предоставляет информацию на русском языке.
HTB - recent articles
- Latest reports • Subjects • PDFs
- 13th European AIDS Conference (EACS), Belgrade, Serbia, 12–15 October 2011
- European guidelines (EACS) – 2011 update
- Raltegravir achieves superiority over efavirenz after four years
- Higher plasma levels of tenofovir and darunavir but not efavirenz in older patients
- Ritonavir levels reduced with high fat meal
- Transplacental transfer of raltegravir and delayed plasma clearance in preterm neonates
- 2nd International Workshop on HIV and Ageing, Baltimore, Maryland, 27–28 October 2011
HTB South - recent articles
- Latest reports • Subjects • PDFs
- HTB SUPPLEMENT: 2011 pipeline report
- Volume 4 Number 3 July/September 2011
- 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention 17–20 July 2011, Rome
- Webcasts for major research at IAS
- Treatment is prevention: ARV treatment in HPTN-052 reduces transmission by at least 96%: single transmission in treatment arm occurred prior to viral suppression
- Daily oral tenofovir/FTC PrEP reduces heterosexual transmission by 63% in the TDF2 study
- Tenofovir/FTC vs tenofovir as daily oral PrEP: preliminary results from Partners PrEP
Q and A - recent questions
- Recent questions and answers • Ask a question • Subjects
- I am recently on Atripla. from 5 days and I feel very dizzy
- Does starting treatment early is better for me?
- Is Viramune XR better for my metabolism?
- Why do I get rejected when I’m honest about my HIV status?
- What is causing me dhiarrhoea and joint pain?
- I’m 40 plus and positive – what is my life expectancy?
- Is it possible that I have TB without any symptoms?
Mini site map
Adapting i-Base materials • Pictures and diagrams • News • Phoneline • Q and A • Order
HIVTRI training partner • HTB • HTB South • ARV4IDUs • Treatment guides • Manual
i-Base on YouTube • About us • Contact • Annual report • Copyright waiver
Contact info
This site complies with the HONcode standard for trustworthy health information. Verify here.
HIV i-Base
4th Floor, 57 Great Suffolk Street, London, SE1 0BB.
Tel + 44 (0) 20 7407 8488. Fax + 44 (0) 20 7407 8489.
Email admin@i-base.org.uk.
Registered charity no: 1081905. Company reg no: 3962064.
HIV i-Base
Treatment phoneline: 0808 800 6013 • Mon-Wed 12-4pm • Office: 020 7407 8488 • Email: admin@i-base.org.uk • Website: www.i-base.info